ASH 2022: Impact of Momelotinib on Patient-Reported Quality of Life for Patients With Myelofibrosis
Posted: 01/11/2023 | By: Chase Doyle

MOMENTUM, a phase III study in symptomatic, anemic patients with myelofibrosis who were previously treated with a JAK inhibitor, showed that momelotinib significantly improved disease-related symptoms compared to danazol. At the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition, Mesa et al presented results from the trial on patient-reported health status and health-related quality of life analyses (Abstract 4351).

Question 1 of 5

What was the primary endpoint of the MOMENTUM study?

Choose 1